(Reuters) - An advisory panel to the U.S. Food and Drug Administration unanimously recommended the use of Novartis AG's anti-inflammation drug in patients with a type of psoriasis, paving the way for its approval. The panel voted 7-0 in favor of the drug's use in plaque-psoriasis, the most common form of the painful, unsightly skin condition. FDA staff reviewers last week had said the drug's benefits outweighed its risk. The injectable biologic, secukinumab, is part of an eagerly anticipated class of drugs called IL-17 inhibitors that have shown unprecedented success in plaque-psoriasis. ...
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment